XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaborative Arrangements and Licensing Agreements (Tables)
 6 Months Ended
Jun. 30, 2024
AstraZeneca [Member]  
Collaborative Arrangements and Licensing Agreements [Abstract]  
Revenue from Collaborative Relationship

During the three and six months ended June 30, 2024 and 2023, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentage amounts):

 
Three Months Ended
June 30,
    
Six Months Ended
June 30,
  
   
2024
    
2023
    
2024
    
2023
  
Revenue from our relationship with AstraZeneca
  
$
15,960
    
$
59,501
    
$
27,645
    
$
83,926
  
Percentage of total revenue
    
7
%
    
32
%
    
8
%
    
26
%
Biogen [Member]  
Collaborative Arrangements and Licensing Agreements [Abstract]  
Revenue from Collaborative Relationship

During the three and six months ended June 30, 2024 and 2023, we earned the following revenue from our relationship with Biogen (in thousands, except percentage amounts):

 
Three Months Ended
June 30,
    
Six Months Ended
June 30,
  
   
2024
    
2023
    
2024
    
2023
  
Revenue from our relationship with Biogen
  
$
138,159
    
$
97,402
    
$
197,395
    
$
167,903
  
Percentage of total revenue
    
61
%
    
52
%
    
57
%
    
53
%
Otsuka [Member]  
Collaborative Arrangements and Licensing Agreements [Abstract]  
Revenue from Collaborative Relationship

During the three and six months ended June 30, 2024 and 2023, we earned the following revenue from our relationship with Otsuka (in thousands, except percentage amounts):

 
Three Months Ended
June 30,
    
Six Months Ended
June 30,
  
   
2024
    
2023
    
2024
    
2023
  
Revenue from our relationship with Otsuka
  
$
18,905
    
$
—
    
$
19,691
    
$
—
  
Percentage of total revenue
    
8
%
    
0
%
    
6
%
    
0
%
Roche [Member]  
Collaborative Arrangements and Licensing Agreements [Abstract]  
Revenue from Collaborative Relationship

During the three and six months ended June 30, 2024 and 2023, we earned the following revenue from our relationship with Roche (in thousands, except percentage amounts):

   
Three Months Ended
June 30,
    
Six Months Ended
June 30,
  
   
2024
    
2023
    
2024
    
2023
  
Revenue from our relationship with Roche
  
$
11,089
    
$
5,754
    
$
22,595
    
$
8,121
  
Percentage of total revenue
    
5
%
    
3
%
    
7
%
    
3
%